J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...
Following after in J&J's Taris-derived pipeline is TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), which started the phase 3 MoonRISe-1 trial in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback